Nomir Medical Technologies Granted European Patent on Core Noveon(R) Technology - MarketWatch.
The Noveon is a light-based system that targets the elimination of bacterial and fungal infections through a unique near-infrared photo-inactivation effect, while preserving healthy tissue and promoting recovery. The patent coverage provides for use of two proprietary near-infrared wavelengths that have proven to damage and eradicate bacteria and fungi in human diseased tissue ranging from onychomycosis (toenail fungus) to MRSA infection in the human nose, without thermal injury to surrounding tissues. Nomir's Chief Scientific Officer, Dr. Eric Bornstein, said, "The granting of this patent is a significant milestone in the evolution of Nomir as a leading photobiology company. We have been developing the Noveon system for five years, and are grateful for the protection that this patent now offers to this unique and proprietary therapy for fighting human infections. This patent covers important systems and is currently integrated into our core medical and dental products and rich research and development pipeline."
